hdac inhibitor rec-2282

Generic: HDAC Inhibitor REC-2282

hdac inhibitor rec-2282: sourced relationships with 1 company · 1 clinical trial tracked.

What we can confirm

1 tracked trial

RECURSION PHARMACEUTICALS, INC. (RXRX)

What it means

Source-backed records connect hdac inhibitor rec-2282 to RXRX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.

BioSniper AIPage evidence connected

Prepared research question

How could hdac inhibitor rec-2282 → RXRX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Neurofibromatosis Type 2

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)

Company	Dated record stage	Indication
RECURSION PHARMACEUTICALS, INC. (RXRX) developer · Reported 2025-02-28 · Current development: unknownSource Neurofibromatosis Type 2	Phase 2/Phase 3	Neurofibromatosis Type 2

Clinical Trial Registry Records (1)

A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas

NCT05130866Registry updated 2026-08-17·Phase 2/Phase 3·RXRX

Terminated

Primary endpoint: Cohort A: Number of Participants with Progression-free survival (PFS) at 6 Months

InterventionalRandomizeddouble25 enrolledStarted 2022-06Completion 2025-0815 sites · United Kingdom, United StatesRecursion Pharmaceuticals Inc.

Frequently asked questions

Which companies have sourced relationships with hdac inhibitor rec-2282?

hdac inhibitor rec-2282 has dated SEC/FDA relationship records for RECURSION PHARMACEUTICALS, INC..

How many clinical trials involve hdac inhibitor rec-2282?

BioSniper tracks 1 clinical trial involving hdac inhibitor rec-2282.